DOCTEUR J.EUBEN
ActiveSummary
DOCTEUR J.EUBEN has been active since 2018 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €18,857 and a net result of €121,511. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 13% of 20,558 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
15-04
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
31-12
Financial
Highest result from 2019 to 2025net €121,511 ▲5%
Operating result €156,377, net result €121,511, both a record.
29-04
NBB filing
Annual accounts filed
financial year 2024 · micro format
2024
15-07
NBB filing
Annual accounts filed
financial year 2023 · micro format
2023
21-03
NBB filing
Annual accounts filed
financial year 2022 · micro format
2022
12-07
NBB filing
Annual accounts filed
financial year 2021 · micro format
2021
31-12
Financial
Liquidity doublescurrent ratio 9.16
Current ratio from 4.52 to 9.16; short-term debt falls from €33,429 to €26,790.
31-12
Financial
Equity above €200,000equity €218,723 ▲80%
A profit in every financial year since 2019 builds equity to €218,723.
12-07
NBB filing
Annual accounts filed
financial year 2020 · micro format
2020
31-12
Financial
Weakest financial yearnet €36,020 ▼50.7%
Net result drops to €36,020, the lowest in the series; recovery starts the following year.
31-12
Financial
Equity above €100,000equity €121,490 ▲42.1%
A profit in every financial year since 2019 builds equity to €121,490.
30-06
NBB filing
Annual accounts filed
financial year 2019 · micro format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 2 deeds read
About the unread acts
We know of 2 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.